Pharming Group N.V. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
18,976.00
34,185.00
31,643.00
31,889.00
58,657.00
80,311
Total Accounts Receivable
615.00
1,410.00
2,993.00
11,386.00
10,183.00
16,001
Inventories
4,763.00
13,404.00
16,229.00
17,941.00
18,334.00
17,315
Other Current Assets
245.00
144.00
227.00
974.00
1,077.00
1,813
Total Current Assets
24,599.00
49,143.00
51,092.00
62,190.00
88,251.00
115,440
Net Property, Plant & Equipment
6,228.00
5,598.00
5,661.00
6,043.00
8,234.00
8,402
Total Investments and Advances
176.00
200.00
200.00
248.00
1,336.00
1,204
Intangible Assets
405.00
777.00
724.00
56,680.00
56,631.00
52,435
Other Assets
-
-
-
1,622.00
2,296.00
2,006
Total Assets
31,408.00
55,718.00
57,677.00
126,783.00
166,190.00
214,569
ST Debt & Current Portion LT Debt
766.00
626.00
3,310.00
26,399.00
22,225.00
Accounts Payable
4,027.00
2,943.00
1,016.00
5,652.00
9,430.00
Other Current Liabilities
8,132.00
11,304.00
9,149.00
19,327.00
26,873.00
Total Current Liabilities
12,925.00
14,873.00
13,475.00
51,378.00
58,528.00
Long-Term Debt
1,207.00
965.00
12,555.00
40,994.00
59,074.00
Deferred Taxes
-
-
-
-
9,442.00
Other Liabilities
12,266.00
10,037.00
7,808.00
6,944.00
29,786.00
Total Liabilities
26,398.00
25,875.00
33,838.00
99,316.00
147,388.00
Common Equity (Total)
5,010.00
29,843.00
23,839.00
27,467.00
18,802.00
Total Shareholders' Equity
5,010.00
29,843.00
23,839.00
27,467.00
18,802.00
Total Equity
5,010.00
29,843.00
23,839.00
27,467.00
18,802.00
Liabilities & Shareholders' Equity
31,408.00
55,718.00
57,677.00
126,783.00
166,190.00

About Pharming Group

View Profile
Address
Darwinweg 24
Leiden Zuid-Holland 2333 CR
Netherlands
Employees -
Website http://www.pharming.com
Updated 07/08/2019
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World.